- IMUNON, Inc. (Nasdaq:IMNN) is advancing its lead candidate, IMNN-001, in Phase 3 clinical trials for advanced ovarian cancer.
- The company executed a stock split and introduced a 15% stock dividend to enhance shareholder value.
- Despite significant clinical progress, IMNN’s stock price has decreased to $8.22, with a market capitalization of approximately $17.43 million.
IMUNON, Inc. (Nasdaq:IMNN) is a clinical-stage company focused on developing DNA-mediated immunotherapy treatments. The company is currently advancing its lead candidate, IMNN-001, in Phase 3 clinical trials for newly diagnosed advanced ovarian cancer. IMUNON operates in a competitive biotech industry, where innovation and clinical progress are key to success.
On August 7, 2025, IMNN executed a stock split, exchanging 20 shares for every 23 shares previously held. This move is part of the company’s broader strategy to enhance shareholder value. Alongside the stock split, IMUNON introduced a 15% stock dividend for shareholders of record on the same date, as highlighted by IMUNON’s President and CEO, Stacy Lindborg, PhD.
The stock split and dividend announcement come amid significant clinical progress. IMUNON’s Phase 3 development of IMNN-001 is a critical milestone, reflecting the company’s commitment to advancing its pipeline. These strategic decisions aim to strengthen shareholder confidence and support the company’s ongoing clinical efforts.
Despite these positive developments, IMNN’s stock is currently priced at $8.22, marking a decrease of 6.22% with a change of $0.55. The stock has fluctuated between $8.09 and $8.91 today, with a 52-week high of $41.22 and a low of $4.83. IMUNON’s market capitalization stands at approximately $17.43 million, with a trading volume of 81,827 shares on the NASDAQ exchange.
